Todays Report: The California State Teachers Retirement System invests in Oxford Immunotec Global PLC (OXFD) Shares

The California State Teachers Retirement System invests in Oxford Immunotec Global PLC (OXFD) Shares

California State Teachers Retirement System raised its position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 9.1% during the second quarter, Holdings Channel reports. The institutional investor owned 46,546 shares of the company’s stock after buying an additional 3,870 shares during the period. California State Teachers Retirement System owned 0.21% of Oxford Immunotec Global PLC worth $419,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of OXFD. Geode Capital Management LLC increased its stake in shares of Oxford Immunotec Global PLC by 32.2% in the first quarter. Geode Capital Management LLC now owns 33,614 shares of the company’s stock worth $333,000 after buying an additional 8,180 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Oxford Immunotec Global PLC by 26.3% in the second quarter. Bank of New York Mellon Corp now owns 51,899 shares of the company’s stock valued at $467,000 after buying an additional 10,809 shares during the period. Renaissance Technologies LLC increased its stake in Oxford Immunotec Global PLC by 51.6% in the first quarter. Renaissance Technologies LLC now owns 81,700 shares of the company’s stock valued at $810,000 after buying an additional 27,800 shares during the period. Kornitzer Capital Management Inc. KS increased its stake in Oxford Immunotec Global PLC by 22.6% in the second quarter. Kornitzer Capital Management Inc. KS now owns 103,700 shares of the company’s stock valued at $933,000 after buying an additional 19,100 shares during the period. Finally, State Street Corp increased its stake in Oxford Immunotec Global PLC by 4.1% in the first quarter. State Street Corp now owns 235,187 shares of the company’s stock valued at $2,329,000 after buying an additional 9,245 shares during the period. 78.02% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) remained flat at $12.71 on Thursday. The stock had a trading volume of 11,890 shares. The company’s 50 day moving average price is $11.68 and its 200 day moving average price is $10.07. Oxford Immunotec Global PLC has a 1-year low of $7.73 and a 1-year high of $14.25. The stock’s market capitalization is $286.85 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last released its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. The firm had revenue of $19.20 million for the quarter, compared to analysts’ expectations of $18.10 million. Oxford Immunotec Global PLC had a negative net margin of 34.33% and a negative return on equity of 27.23%. The business’s quarterly revenue was up 34.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.33) earnings per share. Analysts predict that Oxford Immunotec Global PLC will post ($1.29) EPS for the current fiscal year.

Several equities research analysts recently weighed in on OXFD shares. BTIG Research reissued a “buy” rating and set a $17.00 price objective on shares of Oxford Immunotec Global PLC in a report on Sunday, September 11th. Zacks Investment Research downgraded Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a report on Friday, August 5th. TheStreet raised Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Friday, September 30th. Finally, Piper Jaffray Cos. reissued a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Sunday, June 26th.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Related posts

Leave a Comment